{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059460","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.685342+00:00","generated_at":"2026-06-02T06:28:24.857164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024","bullets":["SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.","CanGarooRM antibiotic-envelope 510(k) submission; positive FDA interactions; clearance anticipated Q2 2024.","Net loss $18.0M includes $9.6M non-cash warrant revaluation; adjusted EBITDA loss improved to $3.6M.","Cash balance $12.6M; preparing for CanGarooRM commercial launch in H2 2024.","Overall net sales $6.7M (+5% YoY); cardiovascular sales declined 56% due to LeMaitre distribution transition."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059460","json":"https://secwatch.observer/filing/0001104659-24-059460.json","markdown":"https://secwatch.observer/filing/0001104659-24-059460.md","text":"https://secwatch.observer/filing/0001104659-24-059460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/0001104659-24-059460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/tm2414063d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:28:24.857164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2626e409e3d84e31144d2552c62f6b44962a256e","claim":"ELUTIA INC. reported first quarter ended March 31, 2024 results: revenue $6.7 million, net income $18.0 million.","evidence_excerpt":"second half of this year. First Quarter 2024 Financial Results For the three-month period ended March 31, 2024, as compared to the same period of 2023: · Overall net sales were $6.7 million, an increase of 5%. · Net sales of SimpliDerm were $3.6 million, compared to $2.3 million, an increase of 55%, as customer awareness and acceptance accelerated within the $1.6","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465924059460/0001104659-24-059460-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$6.7 million"},{"label":"Net income","value":"$18.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}